These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2860 related items for PubMed ID: 28238223

  • 1. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C, Jun M, Badve SV, Pilmore H, White SL, Hawley C, Cass A, Perkovic V, Zoungas S.
    Cochrane Database Syst Rev; 2017 Feb 27; 2(2):CD009966. PubMed ID: 28238223
    [Abstract] [Full Text] [Related]

  • 2. Glucose-lowering agents for treating pre-existing and new-onset diabetes in kidney transplant recipients.
    Lo C, Toyama T, Oshima M, Jun M, Chin KL, Hawley CM, Zoungas S.
    Cochrane Database Syst Rev; 2020 Jul 30; 8(8):CD009966. PubMed ID: 32803882
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Dipeptidyl-peptidase (DPP)-4 inhibitors and glucagon-like peptide (GLP)-1 analogues for prevention or delay of type 2 diabetes mellitus and its associated complications in people at increased risk for the development of type 2 diabetes mellitus.
    Hemmingsen B, Sonne DP, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2017 May 10; 5(5):CD012204. PubMed ID: 28489279
    [Abstract] [Full Text] [Related]

  • 5. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
    Waugh N, Cummins E, Royle P, Clar C, Marien M, Richter B, Philip S.
    Health Technol Assess; 2010 Jul 10; 14(36):1-248. PubMed ID: 20646668
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study.
    Garber AJ, Schweizer A, Baron MA, Rochotte E, Dejager S.
    Diabetes Obes Metab; 2007 Mar 10; 9(2):166-74. PubMed ID: 17300592
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Safety and effectiveness of non-insulin glucose-lowering agents in the treatment of people with type 2 diabetes who observe Ramadan: a systematic review and meta-analysis.
    Gray LJ, Dales J, Brady EM, Khunti K, Hanif W, Davies MJ.
    Diabetes Obes Metab; 2015 Jul 10; 17(7):639-48. PubMed ID: 25777247
    [Abstract] [Full Text] [Related]

  • 10. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T, Engler J, Siebenhofer A, Jeitler K, Berghold A, Horvath K.
    Cochrane Database Syst Rev; 2020 Nov 09; 11(11):CD005613. PubMed ID: 33166419
    [Abstract] [Full Text] [Related]

  • 11. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K, Williams J, Qi YP, Gutman J, Yeung L, Mai C, Finkelstain J, Mehta S, Pons-Duran C, Menéndez C, Moraleda C, Rogers L, Daniels K, Green P.
    Cochrane Database Syst Rev; 2022 Feb 01; 2(2022):. PubMed ID: 36321557
    [Abstract] [Full Text] [Related]

  • 12. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential.
    Mikhail N.
    Vasc Health Risk Manag; 2008 Feb 01; 4(6):1221-7. PubMed ID: 19337535
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Insulin monotherapy compared with the addition of oral glucose-lowering agents to insulin for people with type 2 diabetes already on insulin therapy and inadequate glycaemic control.
    Vos RC, van Avendonk MJ, Jansen H, Goudswaard AN, van den Donk M, Gorter K, Kerssen A, Rutten GE.
    Cochrane Database Syst Rev; 2016 Sep 18; 9(9):CD006992. PubMed ID: 27640062
    [Abstract] [Full Text] [Related]

  • 15. (Ultra-)long-acting insulin analogues for people with type 1 diabetes mellitus.
    Hemmingsen B, Metzendorf MI, Richter B.
    Cochrane Database Syst Rev; 2021 Mar 04; 3(3):CD013498. PubMed ID: 33662147
    [Abstract] [Full Text] [Related]

  • 16. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes.
    Mikhail N.
    Expert Opin Investig Drugs; 2008 Jun 04; 17(6):845-53. PubMed ID: 18491986
    [Abstract] [Full Text] [Related]

  • 17. Interventions for people with type 2 diabetes mellitus fasting during Ramadan.
    Lee SWH, Chen WS, Sellappans R, Md Sharif SB, Metzendorf MI, Lai NM.
    Cochrane Database Syst Rev; 2023 Jul 12; 7(7):CD013178. PubMed ID: 37435938
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Efficacy and safety profile of sitagliptin, vildagliptin, and metformin in newly diagnosed type 2 diabetic subjects.
    Elhini SH, Hussien AK, Omran AAE, Elsayed AA, Saeed H.
    Clin Exp Pharmacol Physiol; 2021 Dec 12; 48(12):1589-1602. PubMed ID: 34333803
    [Abstract] [Full Text] [Related]

  • 20. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin--diabetes control and potential adverse events.
    Ahrén B.
    Best Pract Res Clin Endocrinol Metab; 2009 Aug 12; 23(4):487-98. PubMed ID: 19748066
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 143.